Display options
Cite
Ingle SM, Crane HM, Glass TR, et al. Identifying Risk of Viral Failure in Treated HIV-Infected Patients Using Different Measures of Adherence: The Antiretroviral Therapy Cohort Collaboration. J Clin Med. 2018;7(10)doi: 10.3390/jcm7100328.
Ingle, S. M., Crane, H. M., Glass, T. R., Yip, B., Lima, V. D., Gill, M. J., Hanhoff, N., Ammassari, A., Mugavero, M. J., Tate, J. P., Guest, J., Turner, N. L., May, M. T., & Sterne, J. A. C. (2018). Identifying Risk of Viral Failure in Treated HIV-Infected Patients Using Different Measures of Adherence: The Antiretroviral Therapy Cohort Collaboration. Journal of clinical medicine, 7(10), . https://doi.org/10.3390/jcm7100328
Ingle, Suzanne M, et al. "Identifying Risk of Viral Failure in Treated HIV-Infected Patients Using Different Measures of Adherence: The Antiretroviral Therapy Cohort Collaboration." Journal of clinical medicine vol. 7,10 (2018). doi: https://doi.org/10.3390/jcm7100328
Ingle SM, Crane HM, Glass TR, Yip B, Lima VD, Gill MJ, Hanhoff N, Ammassari A, Mugavero MJ, Tate JP, Guest J, Turner NL, May MT, Sterne JAC. Identifying Risk of Viral Failure in Treated HIV-Infected Patients Using Different Measures of Adherence: The Antiretroviral Therapy Cohort Collaboration. J Clin Med. 2018 Oct 05;7(10). doi: 10.3390/jcm7100328. PMID: 30301179; PMCID: PMC6209956.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2018 Oct 05;7(10). doi: 10.3390/jcm7100328.

Identifying Risk of Viral Failure in Treated HIV-Infected Patients Using Different Measures of Adherence: The Antiretroviral Therapy Cohort Collaboration.

Journal of clinical medicine

Suzanne M Ingle, Heidi M Crane, Tracy R Glass, Benita Yip, Viviane D Lima, M John Gill, Nikola Hanhoff, Adriana Ammassari, Michael J Mugavero, Jan P Tate, Jodie Guest, Nicholas L Turner, Margaret T May, Jonathan A C Sterne

Affiliations

  1. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK. [email protected].
  2. Clinical Epidemiology and Health Services Research Core, Center for AIDS Research, University of Washington, WA 98104, USA. [email protected].
  3. Swiss Tropical and Public Health Institute, CH-4002 Basel, Switzerland. [email protected].
  4. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC V6Z 1Y6, Canada. [email protected].
  5. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC V6Z 1Y6, Canada. [email protected].
  6. Division of Infectious Diseases, University of Calgary, Calgary, AB T2N 4N1, Canada. [email protected].
  7. Southern Alberta Clinic, Calgary, AB T2R 0X7, Canada. [email protected].
  8. Istituto Nazionale Malattie Infettive "L. Spallanzani", IRCCS, 00149 Rome, Italy. [email protected].
  9. Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, AL 35294, USA. [email protected].
  10. Yale University School of Medicine, West Haven, CT 06510, USA. [email protected].
  11. HIV Atlanta VA Cohort Study (HAVACS), Rollins School of Public Health at Emory University, Atlanta, GA 30322, USA. [email protected].
  12. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK. [email protected].
  13. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK. [email protected].
  14. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK. [email protected].

PMID: 30301179 PMCID: PMC6209956 DOI: 10.3390/jcm7100328

Abstract

Adherence to antiretroviral therapy (ART) is critical for successful treatment of Human Immunodeficiency Virus (HIV), but comparisons across settings are difficult because adherence is measured in different ways. We examined utility of different adherence measures for identification of patients at risk of viral failure (VF). Eight cohorts in the ART Cohort Collaboration contributed data from pharmacy refills or self-report questionnaires collected between 1996 and 2013 (

Keywords: HIV; adherence; antiretroviral therapy; cohort studies; viral failure

References

  1. AIDS. 2007 May 31;21(9):1175-83 - PubMed
  2. Antivir Ther. 2004 Apr;9(2):291-6 - PubMed
  3. HIV Med. 2010 Mar;11(3):216-24 - PubMed
  4. Clin Infect Dis. 2011 Feb 15;52(4):493-506 - PubMed
  5. AIDS Behav. 2013 Jan;17(1):284-97 - PubMed
  6. Patient Prefer Adherence. 2014 Jan 13;8:83-91 - PubMed
  7. AIDS Behav. 2006 May;10(3):227-45 - PubMed
  8. Ann Intern Med. 2003 Nov 18;139(10):810-6 - PubMed
  9. Int J STD AIDS. 2004 Dec;15(12):803-10 - PubMed
  10. Clin Infect Dis. 2001 Oct 15;33(8):1417-23 - PubMed
  11. J Clin Epidemiol. 1997 Jan;50(1):105-16 - PubMed
  12. Ann Pharmacother. 2014 May;48(5):589-95 - PubMed
  13. Curr HIV/AIDS Rep. 2009 Nov;6(4):177-86 - PubMed
  14. Int J Epidemiol. 2014 Jun;43(3):691-702 - PubMed
  15. AIDS. 2002 May 3;16(7):1051-8 - PubMed
  16. Int J Epidemiol. 2015 Feb;44(1):58-67 - PubMed
  17. J Acquir Immune Defic Syndr. 2002 May 1;30(1):105-10 - PubMed
  18. Ann Intern Med. 2001 May 15;134(10):968-77 - PubMed
  19. Ann Intern Med. 2000 Jul 4;133(1):21-30 - PubMed
  20. HIV Clin Trials. 2013 Mar-Apr;14(2):68-74 - PubMed
  21. Clin Ther. 2007 Apr;29(4):711-6 - PubMed
  22. J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S79-87 - PubMed
  23. Ann Pharmacother. 2010 May;44(5):800-8 - PubMed
  24. J Pharm Technol. 2009 Jul;25(4):223-229 - PubMed
  25. J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):445-9 - PubMed
  26. J Acquir Immune Defic Syndr. 2010 Jun;54(2):197-203 - PubMed
  27. J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):445-8 - PubMed

Publication Types

Grant support